M&A moves are down, venture rounds few and IPOs nonexistent.
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?